Ledger.

Company

CF Foundation Therapeutics Development Network

Coverage

Stories naming CF Foundation Therapeutics Development Network. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

2 deals

MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis

The MRCF Biomedical Translation Fund has launched Respirion Pharmaceuticals, a Perth biotech developing an inhaled antibiotic for cystic fibrosis, committing up to A$20 million, with up to US$3 million from the CF Foundation.

Also Brandon BioCatalyst portfolio·@AuManufacturing

Something wrong? Tell us